What question did this study set out to answer?

May 17, 2026Eurosurveillance0 citationsOpen Access

Product- and schedule-specific vaccine effectiveness against invasive Haemophilus influenzae serotype b (Hib) disease, The Netherlands, 2005 to 2023

MBMarta BertranNational Institute for Public Health and the Environment BGBrechje de GierNational Institute for Public Health and the Environment TVTatiana Garcia VilaplanaNational Institute for Public Health and the Environment

Key Points

To estimate overall, product- and schedule-specific vaccine effectiveness against invasive Hib disease.
Conducted a matched case-control study from national reference laboratory data (2005-2023).
Matched 10 controls per case by birth date and sex, and obtained vaccination data from the registry.
Estimated matched odds ratios and vaccine effectiveness using conditional logistic regression.
Included 250 Hib cases and 2,487 controls.
Vaccine effectiveness for 11-119 month-olds was 96% (95% CI: 88-99) for DTaP-IPV/Hib, 95% (95% CI: 91-97) for DT3aP-HBV-IPV/Hib, and 98% (95% CI: 94-99) for DT5aP-HBV-IPV-Hib.
No differences observed in vaccine effectiveness by time since vaccination between products or schedules.

Abstract

BACKGROUND Invasive Haemophilus influenzae type b (iHib) disease incidence in 95% for the respective primary series. No differences in VE by time since vaccination were observed between products or schedules. CONCLUSION Changes in VE against iHib after recent product or schedule changes do not explain the increasing iHib incidence. The high VE supports pursuing optimal vaccination coverage.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Bertran et al. (Thu,) studied this question.

synapsesocial.com/papers/6a095bdd7880e6d24efe1abf https://doi.org/https://doi.org/10.2807/1560-7917.es.2026.31.19.2500699

AI से पूछें

Bookmark

View Full Paper